Quarterly report pursuant to Section 13 or 15(d)

Development Awards and Deferred Revenue (Details Narrative)

v3.19.2
Development Awards and Deferred Revenue (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 26, 2018
Apr. 20, 2015
May 31, 2019
Apr. 30, 2019
Mar. 31, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Development Award [Line Items]                      
Additional paid in capital, fair value of warrant issued                 $ 6,215,225    
Amount received upon achievement           $ 2,482,238   $ 2,482,238   $ 1,462,503  
Cystic Fibrosis Foundation Warrants [Member]                      
Development Award [Line Items]                      
Warrant to purchase of common stock 1,000,000                    
Warrant exercisable price per share $ 13.20                    
Warrant exercisable shares of common stock 500,000                    
Warrant expires date Jan. 26, 2025                    
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member]                      
Development Award [Line Items]                      
Upfront payment, received from related party         $ 27,000,000     27,000,000      
Consideration received on milestone payments         $ 173,000,000            
Royalty term description         Ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice.            
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]                      
Development Award [Line Items]                      
Royalty payable               27,000,000      
Cystic Fibrosis Program Related Investment Agreement [Member]                      
Development Award [Line Items]                      
Consideration received on milestone payments               17,500,000      
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                      
Development Award [Line Items]                      
Consideration received on milestone payments       $ 5,000,000              
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                      
Development Award [Line Items]                      
Development award received $ 25,000,000                    
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]                      
Development Award [Line Items]                      
Royalty payment percentage 10.00%                    
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                      
Development Award [Line Items]                      
Warrant exercisable shares of common stock 500,000                    
Investment Agreement [Member] | 2018 CFF Award [Member]                      
Development Award [Line Items]                      
Revenue           $ 2,094,583 $ 853,646 3,980,265 $ 1,804,088    
Investment Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]                      
Development Award [Line Items]                      
Upfront payment, received from related party     $ 27,000,000                
Proceeds from Royalty     $ 2,700,000                
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                      
Development Award [Line Items]                      
Revenue               18,784,775      
Reclassified to contract asset and classified in prepaid expenses               25,000,000      
Additional paid in capital, fair value of warrant issued               $ 6,215,225      
Increase in deferred revenue                   17,500,000  
2015 CFFT Award Agreement [Member]                      
Development Award [Line Items]                      
Revenue                   $ 2,440,195
2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]                      
Development Award [Line Items]                      
Amount received upon achievement   $ 5,000,000                  
2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                      
Development Award [Line Items]                      
Payment due period after the first commercial sale   90 days                  
Royalty payment, sales target   $ 500,000,000                  
2015 CFFT Award Agreement [Member] | Maximum [Member]                      
Development Award [Line Items]                      
Development award received   5,000,000                  
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]                      
Development Award [Line Items]                      
Royalty payable   25,000,000                  
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                      
Development Award [Line Items]                      
Royalty payable   5,000,000                  
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]                      
Development Award [Line Items]                      
Royalty payable   $ 15,000,000